- Subscribe to JETLaw
- Volume 15
- Volume 14
- Volume 13
- Volume 12
- Volume 11
- Volume 10
- Volume 9
- Volume 8
- Volume 7
- Volume 6
- Volume 5
- Volume 4
- Volume 3
- Volume 2
- Publish With JETLAW
Currently viewing the tag: "pharmaceuticals"
In a number of recent cases, the Supreme Court has taken on the pharmaceutical industry, resulting in decisions with important implications for plaintiffs, drug manufacturers, and Americans who purchase pharmaceutical drugs.
On February 22, the Court held in Bruesewitz et al. v. Wyeth Inc. that the National Childhood Vaccine Injury Act of [...]Continue Reading →
In the news . . .
Google and NSA team up to fight cyberattacks.
Scientists discover energy teleportation.
Seventh Circuit upholds prison ban on Dungeons & Dragons against First and Fourteenth Amendment challenge.
Australian copyright holders lose ability to compel ISP assistance. Meanwhile, [...]Continue Reading →
I respect the time, effort, and money that pharmaceutical companies devote to drug research and development, and advertising the drugs that are ultimately developed is an inevitable part of the research and [...]Continue Reading →
Most people agree that a generic biologics pathway for the U.S. Food and Drug Administration (FDA) approval of these drugs would be a boon to consumers, but different parties seem to be at odds on the exact exclusivity period that the pharmaceutical companies should be given from their generic drug competitors.
These generic biologics [...]Continue Reading →
Sometimes it’s hard to have a lot of faith in the FDA– especially in light of recent reports that the Georgia peanut plant at the heart of salmonella-related deaths was home to roaches and other goodies. Well, last week the FDA approved the use of dairy goats by drug manufacturers. [...]Continue Reading →
On October 7, 2008 By JETLaw
Pfizer, Inc., the world’s largest research-based pharmaceutical company, announced on October 1 that it plans to discontinue research and development in the areas of heart disease, cholesterol, obesity and bone health. The company predicated its decision on the scheduled 2011 expiration of the company’s patent for its bestselling, cholesterol-reducing drug, Lipitor. Research [...]Continue Reading →